Sho Inomata
Overview
Explore the profile of Sho Inomata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murakami C, Atsuta-Tsunoda K, Inomata S, Kawai T, Hijikata Y, Dilimulati K, et al.
FEBS Lett
. 2025 Feb;
PMID: 39992810
Phosphatidylcholine- and phosphatidylethanolamine-specific phospholipase C (PC-PLC and PE-PLC) activities, which generate diacylglycerol (DG) and are tricyclodecan-9-yl-xanthogenate (D609)-sensitive, have been detected in both the membrane and cytosolic fractions. We have previously...
2.
Matsumura Y, Inomata S, Yamaguchi H, Watanabe M, Ozaki Y, Muto S, et al.
Ann Thorac Surg Short Rep
. 2025 Jan;
1(1):91-93.
PMID: 39790544
An 18-year-old Japanese youth was transferred to our emergency department because of a traffic accident. He had a past history of total correction for tetralogy of Fallot as an infant....
3.
Murakami C, Dilimulati K, Atsuta-Tsunoda K, Kawai T, Inomata S, Hijikata Y, et al.
J Biol Chem
. 2024 Nov;
300(12):107960.
PMID: 39510177
Phosphatidylcholine (PC)-specific phospholipase C (PC-PLC) (EC 3.1.4.3) and phosphatidylethanolamine (PE)-specific PLC (PE-PLC) (EC 3.1.4.62), which generate diacylglycerol (DG) and are tricyclodecan-9-yl-xanthogenate (D609)-sensitive, were detected in detergent-insoluble fractions of mammalian tissues...
4.
Higuchi M, Inomata S, Yamaguchi H, Saito T, Suzuki H
J Cardiothorac Surg
. 2023 Jul;
18(1):235.
PMID: 37475037
Background: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial...
5.
Takagi H, Muto S, Fukuhara M, Inomata S, Watanabe M, Ozaki Y, et al.
Gan To Kagaku Ryoho
. 2023 Feb;
50(2):177-182.
PMID: 36807166
Immune checkpoint inhibitors(ICIs)could cause immune-related adverse events(irAEs), of which endocrine disorders are relatively common. Symptoms include fatigue, anorexia, and shock, making diagnosis and treatment difficult. This study aimed to analyze...
6.
Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, et al.
Biomedicines
. 2023 Jan;
11(1).
PMID: 36672698
Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene mutations is a combination of an anti-PD-1/PD-L1 antibody...
7.
Takagi H, Matsumura Y, Fukuhara M, Inomata S, Yamaguchi H, Watanabe M, et al.
Cancer Rep (Hoboken)
. 2022 Oct;
5(11):e1731.
PMID: 36196010
Background: Carcinoid tumors can on rare occasions ectopically produce adrenocorticotropic hormone (ACTH), causing Cushing's syndrome, and patients could become immunocompromised. Care must therefore be taken regarding infectious complications. In particular,...
8.
Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, et al.
Gan To Kagaku Ryoho
. 2022 Sep;
49(9):947-949.
PMID: 36156012
Recently, β-catenin mediated immune escape mechanism has been reported in several cancers. We investigated whether β-catenin is associated with resistance to immune checkpoint inhibitor therapy in non-small cell lung cancer....
9.
Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, et al.
Gan To Kagaku Ryoho
. 2022 Sep;
49(9):928-931.
PMID: 36156007
Although the indications for immune checkpoint inhibitors are expanding rapidly, the disease will eventually progress in many patients. Elucidating and overcoming the resistant mechanisms to immune checkpoint inhibitors is a...
10.
Inomata S, Matsumura Y, Kobayashi Y, Yamaguchi H, Watanabe M, Ozaki Y, et al.
Thorac Cancer
. 2022 Sep;
13(21):3076-3079.
PMID: 36134429
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), a rare condition, is characterized by pathological proliferation of neuroendocrine cells. Some of them are localized to the airway mucosa, and others locally...